μ | δ | κ | ORL1 | |||||
---|---|---|---|---|---|---|---|---|
EC50 | Maximal Effect | EC50 | Maximal Effect | EC50 | Maximal Effect | EC50 | Maximal Effect | |
nM | % | nM | % | nM | % | nM | % | |
DAMGO | 13.5 ± 1.9 | 100 | ||||||
DPDPE | 10.5 ± 1.4 | 100 | ||||||
U50,488H | 3.6 ± 0.5 | 100 | ||||||
Nociceptin/OFQ | 0.14 ± 0.02 | 100 | ||||||
NorBUP | 1.5 ± 0.3 | 81 ± 4 | 30.4 ± 3.5 | 96 ± 3 | 7.2 ± 1.3 | 60 ± 2 | 1368 ± 112 | 130 ± 14 |
BUP | 0.08 ± 0.01 | 38 ± 8 | N.S. | 0.04 ± 0.01 | 10 ± 4 | 35 ± 8 | 60 ± 10 | |
(+)-BUP | N.S. | N.S. | N.S. | N.D. |
DAMGO, DPDPE, U50,488H, and N/OFQ were used as full agonists for the μ-, δ-, κ-opioid and the ORL1 receptors, respectively. Data were derived from the curves in Fig. 3.
N.S., no stimulation up to 1 μM; N.D., not determined.